Mechanisms of high-level ceftolozane/tazobactam resistance in Pseudomonas aeruginosa from a severely neutropenic patient and treatment success from synergy with tobramycin

J Antimicrob Chemother. 2019 Jan 1;74(1):269-271. doi: 10.1093/jac/dky393.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Anti-Bacterial Agents / therapeutic use
  • Cephalosporins / pharmacology*
  • Drug Resistance, Bacterial*
  • Drug Synergism
  • Humans
  • Microbial Sensitivity Tests
  • Pseudomonas Infections / drug therapy
  • Pseudomonas Infections / microbiology*
  • Pseudomonas aeruginosa / drug effects*
  • Pseudomonas aeruginosa / isolation & purification
  • Tazobactam / pharmacology*
  • Tobramycin / therapeutic use*
  • Treatment Outcome
  • beta-Lactamase Inhibitors / pharmacology*

Substances

  • Anti-Bacterial Agents
  • Cephalosporins
  • beta-Lactamase Inhibitors
  • ceftolozane, tazobactam drug combination
  • Tazobactam
  • Tobramycin